AMRI

Article

AMRI is a contract research organization with nearly 20 years experience providing customers fully integrated drug discovery, development and small and large scale manufacturing services.

AMRI is a contract research organization with nearly 20 years experience providing customers fully integrated drug discovery, development and small and large scale manufacturing services.

Comprised of 1350+ employees, we have worked with companies in the pharmaceutical, biotechnology, medical, cosmetic and food industries, as well as not-for-profit organizations and educational institutions.

Providing a broad spectrum of services by a team of scientists with an average global Ph.D. density of 50%, AMRI delivers intellectual input, expertise and renowned problem-solving skills “on the bench.”

With locations throughout the world, AMRI has an unmatched ability to provide globally integrated solutions using flexible business models. Most recently, in February 2010, AMRI acquired Excelsyn Ltd (now AMRI UK) in Holywell, Wales, and can now offer customers European-based development and manufacturing capabilities with convenient access to discovery services through our Hungary facility. Additional capabilities and expertise are available in conjunction with our United States and Asia locations.

Recognized as premier provider of CRO services, AMRI is committed to providing the highest quality services and products to its customers.

To learn more about AMRI and our new cost-effective solutions in Europe, contact us at (518) 512-2000 or visit www.amriglobal.com

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content